Reconciliation of GAAP to Non-GAAP Financial Information

(in millions, except per share data)

<table>
<thead>
<tr>
<th></th>
<th>Three Months Ended June 30,</th>
<th></th>
<th>Six Months Ended June 30,</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GAAP net income</strong></td>
<td>$34.9</td>
<td>$36.1</td>
<td></td>
<td>$68.1</td>
</tr>
</tbody>
</table>

Reconciling items:

**Special charges (gains), net**
- Gain on sale of products: - (4.5) - (10.2)
- Impairment of assets: - 2.6 - 2.6
- Litigation reserve: - 1.2 - 1.2
- Gain on patent settlement: - - (20.2)
- Realignment expenses: - - 2.1

**Subtotal special gains, net** - (0.7) - (24.5)

**Provision (benefit) for income taxes**
- Tax effect on non-GAAP adjustments (1): - 1.8 - 11.2
- Tax benefit from reversal of valuation allowance: - (3.7) - (3.7)

**Subtotal provision (benefit) for income taxes, net** - (1.9) - 7.5

**Non-GAAP net income** $34.9 $33.5 $68.1 $65.0

**Non-GAAP earnings per share:**
- Basic non-GAAP earnings per share: $0.61 $0.57 $1.18 $1.10
- Diluted non-GAAP earnings per share (2): $0.57 $0.54 $1.11 $1.04

**Weighted average shares outstanding:**
- Basic: 57.5 58.8 57.7 59.0
- Diluted: 63.0 64.2 63.2 64.4

---

(1) The tax effect on non-GAAP adjustments is calculated using the relevant tax jurisdiction of the transaction applying the local statutory tax rate.

(2) Diluted non-GAAP earnings per share is calculated by adding back to net income $1.0 million for the quarter in interest expense related to the convertible debt for the quarter, and $2.0 million for the six month period, then dividing by the weighted average diluted shares outstanding.